sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_4 ;
    pav:version "20131211" .
  sub:_3 prov:value "Microarray analysis of the transcriptome of H1975 cells treated with BMS-690514 or CDDP. H1975 cells were treated with either 5 µmol/L (1 µmol/L) BMS-690514 and 50 µmol/L (25 µmol/L) CDDP for 24 h (48 h) and subjected to RNA isolation. Total RNA was then retrotranscribed into double-stranded cDNA followed by T7 RNA polymerase?mediated linear amplification, labeling, and hybridization to a human whole genome 44k oligonucleotide array. Samples from treated cultures were compared with cRNAs obtained through the same procedure from untreated cells.  From Supplementary Table S1, which contains a complete list of genes that are transcriptionally modulated by BMS-690514 by a factor higher than 2. n.s., nonstatistically significant P value (>10?5). H1975 cells have a secondary somatic EGFR mutation T790M which confers resistance to erlotinib. BMS-690514, a novel panHER/VEGFR inhibitor described here, exerted antiproliferative and pro-apoptotic effects on NSCLC cell lines, with prominent efficacy on H1975 cells expressing the T790M mutation.(I included only 24h time points-JSP)  " ;
    prov:wasQuotedFrom pubmed:17616683 .
  sub:_4 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:17616683 ;
    prov:wasDerivedFrom beldoc: , sub:_3 .
}